Breathe Well Live Well
|
AstraZeneca licenses rights to Synairgen asthma drug
Yahoo News LONDON (Reuters) – AstraZeneca has struck a deal worth up to $232 million in milestone payments to license in rights to a drug from Synairgen for viral-induced exacerbation in asthma. Britain's second biggest drugmaker – subject of a takeover bid by … |
View full post on asthma – Google News
|
AstraZeneca Asthma Med Injunction Rolled Into Merits Trial
Law360 (subscription) Law360, Los Angeles (June 04, 2014, 10:08 PM ET) — A New Jersey federal judge on Wednesday didn't rule on whether she would stop AstraZeneca PLC's competitors from launching generic versions of its pediatric asthma medication, saying … |
View full post on asthma – Google News
|
Arthritis, lupus and asthma data a shot in arm for AstraZeneca
Reuters Benralizumab and tralokinumab both showed improvements in control of asthma in patients with specific, severe forms of the breathing disorder. All the drugs are being developed by MedImmune, the U.S.-based biotech company acquired by AstraZeneca in … |
View full post on asthma – Google News
Yahoo News |
UPDATE 1-Arthritis, lupus and asthma data a shot in arm for AstraZeneca
Reuters Benralizumab and tralokinumab both showed improvements in control of asthma in patients with specific, severe forms of the breathing disorder. All the drugs are being developed by MedImmune, the U.S.-based biotech company acquired by AstraZeneca in … Arthritis, lupus and asthma data a shot in arm for AstraZeneca AstraZeneca: Mavrilimumab Produces Rapid Improvement In Signs, Symptoms … AstraZeneca Says MedImmune Phase II Trials Data Positive |
View full post on asthma – Google News
Drug Discovery & Development |
Cancer Research UK to Repurpose AstraZeneca Asthma Drug for Kidney Cancer
Genetic Engineering News AZD2098 was originally designed to treat asthma. CRUK says this deal with AZ will enable its Drug Development Office (DDO) to complete preclinical development and carry out early clinical trials of the compound to see if it can benefit kidney cancer … Cancer Research UK, AstraZeneca To Repurpose Asthma Drug for Kidney Cancer |
View full post on asthma – Google News
Drug Discovery & Development |
Cancer Research UK, AstraZeneca To Repurpose Asthma Drug for Kidney Cancer
Drug Discovery & Development Cancer Research UK and Cancer Research Technology–the charity's development and commercialization arm–have reached an agreement with AstraZeneca to take AZD2098, an experimental drug originally designed for asthma, into a clinical trial to treat … Cancer Research UK to Repurpose AstraZeneca Asthma Drug for Kidney Cancer |
View full post on asthma – Google News
|
ASTRAZENECA PLC : Assessing Your Asthma is Key to Taking Control
4-traders (press release) WILMINGTON, Del., May 13, 2013 /PRNewswire/ — Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy … |
View full post on asthma – Google News
 IBTimes.co.uk |
AstraZeneca wins temporary block on Actavis asthma drug
4-traders (press release) AstraZeneca (>> AstraZeneca plc) has secured a temporary block on U.S. sales of generic copies of its Pulmicort Repsules asthma drug by Actavis (>> Actavis Inc). AstraZeneca (>> AstraZeneca plc) has secured a temporary block on U.S. sales of generic … AstraZeneca Loses US Patent Protection for Asthma Drug AstraZeneca's Kid Asthma Drug Patent Invalid, Judge Says Blow for AstraZeneca in USA over asthma drug patents |
View full post on asthma – Google News
IBTimes.co.uk |
AstraZeneca Loses US Patent Protection for Asthma Drug
Fox Business A patent protecting AstraZeneca's (AZN) Pulmicort Respules asthma drug in the U.S. was deemed invalid on Tuesday, paving the way for a generic version of the drug to hit store shelves. The company said on Tuesday a district court in New Jersey ruled in … AstraZeneca Loses US Patent on Asthma Drug US court blow for AstraZeneca on asthma drug Teva loses exclusivity on AstraZeneca asthma drug |
View full post on asthma – Google News
IBTimes.co.uk |
AstraZeneca Loses US Patent on Asthma Drug
IBTimes.co.uk Apotex and Actavis had received approval from the US Food and Drugs Administration (FDA), but they are yet to launch generic versions of the medicine, which is used to control and prevent asthma symptoms in children aged between 12 months to 8 years. US court blow for AstraZeneca on asthma drug AstraZeneca to contest US court ruling over asthma medicine AstraZeneca loses US drug patent judgment |
View full post on asthma – Google News